Genetic Modification of Tumor-Infiltrating Lymphocytes
T cell differentiation status
T cell subsets
adoptive cell therapy
chimeric antigen receptors
rapid expansion protocol
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
07
2020
accepted:
24
11
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Adoptive T cell therapy (ACT) holds great promise for cancer treatment. One approach, which has regained wide interest in recent years, employs antitumor T cells isolated from tumor lesions ("tumor-infiltrating lymphocytes" or TIL). It is now appreciated that a considerable proportion of anti-melanoma TIL recognize new HLA-binding peptides resulting from somatic mutations, which occurred during tumor progression. The clinical efficacy of TIL can potentially be improved
Identifiants
pubmed: 33488585
doi: 10.3389/fimmu.2020.584148
pmc: PMC7817656
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Chimeric Antigen
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
584148Informations de copyright
Copyright © 2021 Weinstein-Marom, Gross, Levi, Brayer, Schachter, Itzhaki and Besser.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cytotherapy. 2014 May;16(5):619-30
pubmed: 24439255
Cancer Control. 2013 Oct;20(4):289-97
pubmed: 24077405
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32152221
Front Immunol. 2017 Aug 02;8:908
pubmed: 28824634
Am J Hematol. 2018 Dec;93(12):1485-1492
pubmed: 30187944
J Immunother. 2011 Mar;34(2):212-20
pubmed: 21304398
J Immunother. 2008 Oct;31(8):742-51
pubmed: 18779745
J Clin Invest. 2019 Oct 1;129(10):4151-4164
pubmed: 31449054
J Immunother. 2009 May;32(4):415-23
pubmed: 19342963
J Immunother. 2019 Feb/Mar;42(2):43-50
pubmed: 30489430
Isr Med Assoc J. 2006 Mar;8(3):164-8
pubmed: 16599050
J Immunol. 2018 Nov 15;201(10):2959-2968
pubmed: 30305327
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
J Immunother. 2012 Nov-Dec;35(9):651-60
pubmed: 23090074
Nat Rev Immunol. 2012 Mar 22;12(4):269-81
pubmed: 22437939
J Immunother. 2016 Feb-Mar;39(2):60-70
pubmed: 26849075
Hum Gene Ther. 2008 May;19(5):496-510
pubmed: 18444786
Clin Exp Immunol. 2015 Nov;182(2):220-9
pubmed: 26212048
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753545
Immunotherapy. 2016;8(1):35-43
pubmed: 26653685
J Clin Invest. 2008 Jan;118(1):294-305
pubmed: 18060041
Front Immunol. 2020 Jun 26;11:1215
pubmed: 32695101
J Immunother. 2017 Feb/Mar;40(2):39-50
pubmed: 28005579
Blood. 2014 Jun 12;123(24):3750-9
pubmed: 24782509
Immunotherapy. 2013 Jan;5(1):79-90
pubmed: 23256800
Clin Cancer Res. 2010 May 1;16(9):2646-55
pubmed: 20406835
Cancer J. 2015 Nov-Dec;21(6):465-9
pubmed: 26588677
N Engl J Med. 1990 Aug 30;323(9):570-8
pubmed: 2381442
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Clin Cancer Res. 2015 May 15;21(10):2278-88
pubmed: 25695689
Ann Oncol. 2019 Dec 1;30(12):1902-1913
pubmed: 31566658
J Immunol. 2010 Jan 1;184(1):452-65
pubmed: 19949105
Mol Carcinog. 2020 Jul;59(7):736-744
pubmed: 32250515
Clin Cancer Res. 2013 Sep 1;19(17):4792-800
pubmed: 23690483